Novartis Oncology Cancer Clinical Trials
Clinical Trials
Providing Access to Clinical Trial Information
About our Clinical Trials
Novartis is currently conducting clinical trials in a number of disease areas. Novartis is recruiting patients for ongoing clinical trials in the United States. Learn more about trials currently enrolling patients at our Online Patient Recruitment site. There you can learn about the different types of clinical trials that we are performing, their preliminary screening criteria and other important answers to many common questions.
![Thewideprogram [Everolimus/Afinitor]](/research-innovation/images/wide_logo.jpg){kind=logo}
The WIDE (Worldwide Initiative to Develop Everolimus) Program is a global initiative that encompasses a broad range of malignancies. Through this program, Novartis Oncology is conducting clinical studies of everolimus as a single agent and in combination with other anticancer treatments.
This website provides a concise overview of phase II and phase III clinical trials with everolimus (RAD001). All of these oncology trials are being conducted within the WIDE Program—and are either enrolling or will soon be enrolling participants. We hope that you will keep these clinical trials in mind when treating oncology patients who may be appropriate candidates for participation in a clinical trial.
thewideprogram.com [Everolimus/Afinitor]
![Pasprttrials [SOM230/Pasireotide]](/research-innovation/images/pasport_logo.jpg){kind=logo}
PASPORT (PASireotide clinical trial PORTfolio) is a large-scale, worldwide clinical trial program evaluating pasireotide (SOM230) in patients with:
- Pituitary tumors (including registration studies in acromegaly and Cushing’s disease)
- Neuroendocrine tumors (including registration studies in carcinoid tumors)
- Rare neuroendocrine tumors of the pituitary and pancreas
- Other solid tumors
- Nelson’s syndrome
PASPORT will assess the efficacy and safety of pasireotide in the treatment of patients with these often difficult-to-treat tumors and tumor-associated disorders.
pasporttrials.com [SOM230/Pasireotide]
![Goldtrials [TK1258/Dovitinib]](/research-innovation/images/logo.gif){kind=logo}
The GOLD (Global Oncologic Learnings for Dovitinib) Trials are a series of global initiatives led by Novartis that encompass a broad range of malignancies, such as renal cell carcinoma (RCC), breast cancer, gastric cancer, hepatocellular carcinoma (HCC), multiple myeloma, and urothelial cancer. Through this program, Novartis is conducting clinical studies of dovitinib (TKI258) as a single agent and in combination with other agents.1
1. Data on file. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2010.
www.goldtrials.com [TK1258/Dovitinib]
NovartisClinicalTrials.com (For U.S. Residents only.) ›
Novartis Clinical Trials Results Database
The purpose of this clinical trial results database is to increase transparency of Novartis clinical trials by making objective, scientific information about those trials publicly available in a standard, summarized format. Novartis clinical trials are clinical trials which are sponsored by Novartis or any of its affiliates.
The nature and purpose of this clinical trial results database is strictly non-promotional.
Novartis Clinical Trials Results Database ›
ClinicalTrials.gov
ClinicalTrials.gov is a website service provided by the United States National Institutes of Health (NIH). The NIH, through its National Library of Medicine, has developed this website in collaboration with the Food and Drug Administration (FDA), as a result of the FDA Modernization Act, which was passed into law in November 1997.
Click here to go directly to Novartis clinical trials posted on ClinicalTrials.gov
International Federation of Pharmaceutical Manufacturers Associations (IFPMA) Clinical Trials Portal
This service is provided by the IFPMA, on behalf of its Member Companies and Associations. The portal has been designed as a single entry allowing you to search for comprehensive information on on-going clinical trials (registry) or results of completed trials (database) conducted by the innovative pharmaceutical industry.
SEARCH OUR WEBSITES
PRODUCTS
At Novartis Oncology, we strive to provide a broad range of innovative, practical solutions and authoritative resource therapies.
PRODUCT PIPELINE
View the depth and breadth of our research portfolio, with innovative compounds in all phases of development - from preclinical to phase III.
ABOUT NOVARTIS ONCOLOGY
We deliver a broad range of innovative therapies, cancer resources and oncology drugs to improve and extend the lives of cancer patients.
CAREERS AT NOVARTIS
Our success depends entirely on the creativity, performance and achievement of our associates at all levels.
